Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy
Standard
Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy. / Grupp, Katharina; Höhne, Thorsten Simon; Prien, Kristina; Hube-Magg, Claudia; Tsourlakis, Maria Christina; Sirma, Hüseyin; Pham, Taher; Heinzer, Hans; Graefen, Markus; Michl, Uwe; Simon, Ronald; Wilczak, Waldemar; Izbicki, Jakob; Sauter, Guido; Minner, Sarah; Schlomm, Thorsten; Steurer, Stefan.
In: EXP MOL PATHOL, Vol. 95, No. 2, 01.10.2013, p. 227-34.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy
AU - Grupp, Katharina
AU - Höhne, Thorsten Simon
AU - Prien, Kristina
AU - Hube-Magg, Claudia
AU - Tsourlakis, Maria Christina
AU - Sirma, Hüseyin
AU - Pham, Taher
AU - Heinzer, Hans
AU - Graefen, Markus
AU - Michl, Uwe
AU - Simon, Ronald
AU - Wilczak, Waldemar
AU - Izbicki, Jakob
AU - Sauter, Guido
AU - Minner, Sarah
AU - Schlomm, Thorsten
AU - Steurer, Stefan
N1 - © 2013.
PY - 2013/10/1
Y1 - 2013/10/1
N2 - The extracellular matrix metalloproteinase inducer CD147 has been suggested as a prognostic marker in prostate cancer. CD147 expression was analyzed by immunohistochemistry on a tissue microarray containing 11,152 prostate cancer specimens. Results were compared to tumor phenotype, biochemical recurrence, ERG status and deletions on PTEN, 3p13, 6q15 and 5q21. CD147 expression was strong in benign prostatic glands and often reduced in prostate cancers. CD147 immunostaining was found in 71.7% of 7628 interpretable cases. CD147 staining was considered strong in 34.6%, moderate in 24.3% and weak in 12.8% of cancers while 28.3% did not show any CD147 reactivity. Reduced CD147 staining was strongly associated with both TMPRSS2-ERG-rearrangement and ERG expression (p<0.0001 each). Within the subgroups of ERG positive and negative cancers, deletions of PTEN, 3p13, 6q15 and 5q21 were unrelated to the CD147 expression status. Decreased CD147 expression was significantly linked to high preoperative PSA values, high Gleason grade, advanced tumor stage (p<0.0001 each), and positive lymph node involvement (p=0.0026) in all cancers. There was a marginal, but statistically significant, association of reduced CD147 expression with early biochemical recurrence (p=0.0296). The significant reduction of CD147 expression in ERG positive prostate cancer provides further evidence for marked biological differences between "fusion type" and "non-fusion type" prostate cancer. Despite a weak association with PSA recurrence, CD147 cannot be considered a relevant prognostic biomarker.
AB - The extracellular matrix metalloproteinase inducer CD147 has been suggested as a prognostic marker in prostate cancer. CD147 expression was analyzed by immunohistochemistry on a tissue microarray containing 11,152 prostate cancer specimens. Results were compared to tumor phenotype, biochemical recurrence, ERG status and deletions on PTEN, 3p13, 6q15 and 5q21. CD147 expression was strong in benign prostatic glands and often reduced in prostate cancers. CD147 immunostaining was found in 71.7% of 7628 interpretable cases. CD147 staining was considered strong in 34.6%, moderate in 24.3% and weak in 12.8% of cancers while 28.3% did not show any CD147 reactivity. Reduced CD147 staining was strongly associated with both TMPRSS2-ERG-rearrangement and ERG expression (p<0.0001 each). Within the subgroups of ERG positive and negative cancers, deletions of PTEN, 3p13, 6q15 and 5q21 were unrelated to the CD147 expression status. Decreased CD147 expression was significantly linked to high preoperative PSA values, high Gleason grade, advanced tumor stage (p<0.0001 each), and positive lymph node involvement (p=0.0026) in all cancers. There was a marginal, but statistically significant, association of reduced CD147 expression with early biochemical recurrence (p=0.0296). The significant reduction of CD147 expression in ERG positive prostate cancer provides further evidence for marked biological differences between "fusion type" and "non-fusion type" prostate cancer. Despite a weak association with PSA recurrence, CD147 cannot be considered a relevant prognostic biomarker.
KW - Adult
KW - Aged
KW - Antigens, CD147
KW - Humans
KW - Immunohistochemistry
KW - In Situ Hybridization, Fluorescence
KW - Male
KW - Middle Aged
KW - Neoplasm Recurrence, Local
KW - Oncogene Proteins, Fusion
KW - Prostate-Specific Antigen
KW - Prostatectomy
KW - Prostatic Neoplasms
KW - Tissue Array Analysis
KW - Tumor Markers, Biological
U2 - 10.1016/j.yexmp.2013.08.002
DO - 10.1016/j.yexmp.2013.08.002
M3 - SCORING: Journal article
C2 - 23948277
VL - 95
SP - 227
EP - 234
JO - EXP MOL PATHOL
JF - EXP MOL PATHOL
SN - 0014-4800
IS - 2
ER -